GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Star Lake Bioscience Co Inc (SHSE:600866) » Definitions » Debt-to-EBITDA

Star Lake Bioscience Co (SHSE:600866) Debt-to-EBITDA : 3.10 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Star Lake Bioscience Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Star Lake Bioscience Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2,591 Mil. Star Lake Bioscience Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥1,705 Mil. Star Lake Bioscience Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥1,384 Mil. Star Lake Bioscience Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 3.10.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Star Lake Bioscience Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:600866' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.51   Med: 1.62   Max: 11.58
Current: 3.68

During the past 13 years, the highest Debt-to-EBITDA Ratio of Star Lake Bioscience Co was 11.58. The lowest was -8.51. And the median was 1.62.

SHSE:600866's Debt-to-EBITDA is ranked worse than
73.63% of 273 companies
in the Biotechnology industry
Industry Median: 1.3 vs SHSE:600866: 3.68

Star Lake Bioscience Co Debt-to-EBITDA Historical Data

The historical data trend for Star Lake Bioscience Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Star Lake Bioscience Co Debt-to-EBITDA Chart

Star Lake Bioscience Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.37 1.55 11.58 1.69 2.23

Star Lake Bioscience Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.16 6.65 2.88 3.64 3.10

Competitive Comparison of Star Lake Bioscience Co's Debt-to-EBITDA

For the Biotechnology subindustry, Star Lake Bioscience Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Star Lake Bioscience Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Star Lake Bioscience Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Star Lake Bioscience Co's Debt-to-EBITDA falls into.



Star Lake Bioscience Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Star Lake Bioscience Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2450.11 + 1760.667) / 1890.617
=2.23

Star Lake Bioscience Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2590.574 + 1705.445) / 1384.344
=3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Star Lake Bioscience Co  (SHSE:600866) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Star Lake Bioscience Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Star Lake Bioscience Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Star Lake Bioscience Co (SHSE:600866) Business Description

Traded in Other Exchanges
N/A
Address
No. 67 Gongnong North Road, Guangdong Province, Zhaoqing, CHN, 526060
Star Lake Bioscience Co Inc is a China-based Pharmaceutical manufacturer. The company is mainly engaged in the research, development, production, and sales of chemical raw materials and pharmaceutical intermediates. Products offered by the company include proline, guanosine, adenosine, adenine, adefovir dipivoxil, memantine hydrochloride, Proline, threonine, lysine, among others. Its products are used in food processing, feed processing, and pharmaceutical manufacturing. Star Lake sells its products through direct sales and distributors in China and overseas markets.

Star Lake Bioscience Co (SHSE:600866) Headlines

No Headlines